A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
The purpose of the current study is to assess safety/tolerability and key pharmacodynamic
 (PD) effects that are considered to be associated with clinical benefit (reduction of total
 IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also
 known as IMVT-1401) compared to placebo.
Inclusion Criteria:

 1. Male or female ≥ 18 years of age.

 2. Myasthenia Gravis Foundation of America (MGFA) Class II-IVa and likely not in need of
 a respirator for the duration of the study as judged by the Investigator.

 3. QMG score ≥12 at Screening and Baseline.

 Other, more specific inclusion criteria are defined in the protocol.

 Exclusion Criteria:

 1. Use of rituximab, belimumab, eculizumab or any monoclonal antibody for
 immunomodulation within 6 months prior to first dosing.

 2. Immunoglobulins given by SC, IV (IVIG), or intramuscular route, or
 plasmapheresis/plasma exchange (PE) within 4 weeks before Screening.

 3. Thymectomy performed < 12 months prior to screening.

 4. Total IgG level <6 g/L (at screening).

 5. Absolute neutrophil count <1500 cells/mm3(at screening).

 Other, more specific exclusion criteria are defined in the protocol